Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14582764 | 0.71 | CYP3A4 (0.42) | CYP3A4ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL2516601 | 0.69 | HSD17B10 (0.41) | CYP3A4ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL24476713 | 0.67 | MAPT (0.46) | CYP3A4ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL2852558 | 0.67 | CYP3A4 (0.47) | CYP3A4ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL29871387 | 0.67 | CYP3A4 (0.47) | CYP3A4ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL604812 | 0.66 | ALDH1A1 (0.60) | CYP3A4ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL30373734 | 0.66 | ALDH1A1 (0.60) | CYP3A4ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL17965508 | 0.65 | LMNA (0.34) | ALDH1A1HSD17B10TSHRKDM4EMAPT | |
| SCHEMBL7905037 | 0.65 | CYP3A4 (0.41) | CYP3A4ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL4337983 | 0.65 | LIMK1 (0.36) | ALDH1A1HSD17B10CYP2A6RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | SHAPIRO STANLEY S (US) | 2012-02-02 | — | — | US | claimed |
| US-8034941-B2 | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-11 | — | — | US | claimed |
| US-20090258856-A1 | IMIDAZOPYRIDAZINONE AND IMIDAZOPYRIDONE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | claimed |
| US-7566707-B2 | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-28 | — | — | US | claimed |
| EP-1641799-B1 | IMIDAZO-PYRIDAZINONE DERIVATIVES AND IMIDAZO-PYRIDONE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2008-03-12 | — | — | EP | claimed |
| US-20050059607-A1 | Process for preparing peptidyl heterocyclic ketone derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-17 | — | — | US | claimed |
| US-20050026921-A1 | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| CN-1146575-C | Peptidyl heterocycles useful in the treatment of thrombin related disorders | ��λҩƷ��˾ | 2004-04-21 | — | — | CN | claimed |
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | COSTANZO MICHAEL J (US) | 2003-01-09 | — | — | US | claimed |
| EP-0833839-B1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMA CORP (US) | 2003-01-08 | — | — | EP | claimed |
| EP-1147097-A1 | PEPTIDYL HETEROCYCLIC KETONES USEFUL AS TRYPTASE INHIBITORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000044733-A1 | PEPTIDYL HETEROCYCLIC KETONES USEFUL AS TRYPTASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-08-03 | — | — | WO | claimed |
| CN-1234735-A | Method for treating skin pigmentation | JOHNSON & JOHNSON CONSUMER (US) | 1999-11-10 | — | — | CN | claimed |
| WO-1999004752-A9 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER (US) | 1999-04-08 | — | — | WO | claimed |
| CN-1192747-A | Peptidyl heterocyclic compounds for the treatment of thrombin-related diseases | ORTHO PHARMA CORP (US) | 1998-09-09 | — | — | CN | claimed |
| EP-0833839-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1996040742-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATEDDISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040741-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040748-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| US-5523308-A | SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES | ORTHO PHARMACEUTICAL CORPORATION | 1996-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | TYR, MC1R, NQO1 | CYP3A4 2189/4885ALDH1A1 1082/4885HSD17B10 1273/4885 |
| US-20090258856-A1 | IMIDAZOPYRIDAZINONE AND IMIDAZOPYRIDONE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | CYP3A4 14/4885ALDH1A1 213/4885HSD17B10 1027/4885 |
| US-20050059607-A1 | Process for preparing peptidyl heterocyclic ketone derivatives | CMA1, TPSB2, TPSAB1 | CYP3A4 330/4885ALDH1A1 1574/4885HSD17B10 1041/4885 |
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | CMA1, TPSB2, TPSAB1 | CYP3A4 978/4885ALDH1A1 1904/4885HSD17B10 1036/4885 |
| US-20050026921-A1 | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | CYP3A4 12/4885ALDH1A1 239/4885HSD17B10 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.